Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

HCRN study in Merkel cell now enrolling

A new Hoosier Cancer Research Network clinical trial studying Merkel cell carcinoma is currently recruiting subjects.

The trial, A Single Arm Phase II Study with Safety Run-in of Peptide Receptor Radionuclide Therapy (PRRT) in Combination with Immunotherapy for Patients with Merkel Cell Cancer (HCRN-MCC20-443; iPRRT Study), is led by Pashtoon Kasi, MD, MS, of Cornell University and is currently recruiting subjects at New York-Presbyterian/Weill Cornell Medical Center.

The purpose of this study is to find out what effects an immunotherapy drug called pembrolizumab combined with a radioactive drug called lutetium Lu 177 dotatate (Lutathera®) have on patients with Merkel cell carcinoma. Pembrolizumab works by helping a patient’s immune system to fight cancer. Lutathera works by killing cancer cells.

The study design will be a single arm phase 2 study in patients who have progressed on immunotherapy and who are candidates to continue pembrolizumab.

It is supported by Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, and the Gastro-IntestinaI Research Foundation (GIRF).

Learn more about this clinical trial at: https://clinicaltrials.gov/study/NCT05583708.

About Hoosier Cancer Research Network:

Hoosier Cancer Research Network conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has conducted more than 230 trials in a variety of cancer types and supportive care, resulting in more than 350 publications. More than 9,000 subjects have participated in Hoosier Cancer Research Network clinical trials.